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Abstract 
 
Chronic myeloid leukemia is a myeloproliferative neoplasm that results due to the expression of BCR/ABL P210 
oncoprotein in hematopoietic stem cells. This oncoprotein causes constitutive expression of tyrosine kinase and 
disrupts normal signaling pathways of cell cycle progression and differentiation. The use of targeted therapy, 
tyrosine kinase inhibitors (TKIs), although proved to be useful, poor drug response, drug resistance, adverse side 
effects, high cost has posed a severe threat to CML patients. This has shifted the attention of the scientific 
community to search for a more viable alternative that can tackle not only TKI related problems but also modulate 
the leukemogenic signaling pathways by silencing Bcr/Abl expression at the transcript level. MicroRNAs provide a 
beautiful avenue of therapeutic research in haematological malignancies including CML. They are promising 
prognostic as well diagnostic molecules, and with rapid advancement in miRNA based research and underlying 
signaling network in CML, the use of miRNA as prognostic, diagnostic biomarker or as a therapeutic agent alone, or 
in combination with TKIs is sure to see the light of the day. This paper is an endeavour to synthesize our present 
knowledge about CML, the signaling pathways involved in the disease and importance of microRNA in CML 
emphasizing on why microRNA is a better alternative than the currently available TKIs. 
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Introduction  
Leukemia: Du and Chen defines leukemia as a clonal 
malignant hematopoietic stem cell (HSC) disease [1]. 
It belongs to the category of cancer that usually 
begins in the blood-forming cells of the bone 
marrow, and once the leukemic cells overcrowd the 
normal cells, the disease spreads to blood. It is 
characterized by the abnormal proliferation of blood 
precursor cells of myeloid or lymphoid origin [2]. 
The enormous number of immature blood cells 
disrupts the production of functional blood cells. 
Leukemia is categorized according to cell type 
(myeloid/myelogenous orlymphocytic/lymphoblastic) 
and cellular maturity (acute or chronic). There are 
four major types of leukemia, viz: Acute 
Myelogenous Leukemia (AML), Acute Lymphocytic 
Leukemia (ALL), Chronic Myelogenous Leukemia 
(CML) and Chronic Lymphocytic Leukemia (CLL).  
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The incidence of leukemia: Globally it is the sixth 
most life-threatening cancer whose incidence rate has 
not decreased over the years. According to the World 
Health Organization (WHO) databases, the global 
incidence of leukemia varies geographically with a 
male-to-female ratio of 1.4:1 [3]. It occurs in adults 
above 55 years and children below 15 years. 
Leukemia is among the most prevalent childhood 
cancer. In India, the female to male ratio is 1:0.9 to 
1:5.6 with maximum cases in North India and a 
minimum in the North East. These statistics may not 
be absolute because of issues like under-reporting. 
Thus the quality and inclusiveness of such reports in 
registries are important [4, 5]. 
Risk Factors in Leukemia: Leukemia is a genetic 
disease which means that mutation(s) caused in the 
target gene(s) may or may not be heritable. Although 
the exact cause of leukemia is not known several  
studies, have shown that there may be a genetic 
predisposition to developing leukemia and factors 
such as [6, 7] 
a.  regular cigarette smoking,  
b. chemicals like benzene mostly present in 
gasoline, rubber, and shoe-making plants, 
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c. chemotherapeutic drugs like alkylating agents, 
platinum agents, topoisomerase II inhibitors, 
d. genetic disorders such as Down’s Syndrome, 
Klinefelter syndrome, Fanconi anemia, 
e. blood disorders like myelodysplasia, 
polycythemia vera, primary thrombocythemia 
f. gender (males are slightly more prone to develop 
leukemia) 
g. race (European people have a greater tendency to 
get CLL) 
h. family history (applies to cases of CLL)   
i. viral infection (infection with human T-cell 
lymphoma/leukemia virus-1 increases the risk of 
ALL) 
j. age (risk of developing AML and CLL increases 
with age) contributes to the occurrence of the 
disease. 
Besides genetic factors, epigenetic factors like DNA 
methylation, histone modifications also play an 
integral role in the progression of leukemia [8]. 
Philadelphia (Ph) chromosome: Boveri stated that 
cancer cells contain ‘growth stimulatory 
chromosomes’ that play a pivotal role in malignancy. 
Janet Rowley has also emphasized the fact [9]. One 
such chromosome is the Philadelphia chromosome, 
first identified by Rowley.Double-stranded breaks 
(DSBs) followed by balanced reciprocal translocation 
on the long arm (q) of chromosome 9 proximal to 
Abelson murine leukemia viral oncogene homolog 
(Abl) gene and on long arm of chromosome 22 near 
Breakpoint Cluster Region (Bcr) gene results into a 
shortened chimeric chromosome 22 called 
Philadelphia chromosome (named after its place of 
discovery) [9, 10, 11, 12] (Figure 1) and reciprocal 
Abl/Bcr on chromosome 9 [12,13]. The fusion is 
between 3’ region of Abl and 5’ region of Bcr [12, 
14].Abl/Bcr gene is transcriptionally active, yet no 
functional role of it has been identified inCML, and 
no ABL/BCR protein has been found [12], whereas 
the discovery of Bcr/Abl gene by Nowell and 
Hungerford in 1960 has revolutionized the concept of 
hematopoietic malignancies.The Bcr/Abl oncogene 
(now officially called Bcr/Abl1)was discovered in 
1985.  
 
Figure 1: Formation of Philadelphia chromosome 
The frequency of such DSBs is enhanced by ionizing 
radiation [11]. A typical cell being intolerant to DSB 
activates the cellular repair machinery which then 
joins the broken ends. Non-homologous end joining 
(NHEJ) though not exclusive but predominant in 
eukaryotic cells is the possible mechanism of 
repair[15, 16]. After translocation, NHEJ results in 
22q- and 9q+.It is of particular note here that 
homologous sequences have also been identified in 
chromosomes 9 and 22 and in interphase (S and G2 
phases)  they may be present in proximity which 
might facilitate their recombination [11, 13, 14, 17]. 
Thus, it can be said that the translocation is not a 
random event. 
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Figure 2: Detailed features of Bcr and Abl genes. 
Interestingly, Bcr/Abl transcripts can also be detected 
in healthy individuals if the PCR technique used is 
sensitive enough but these individuals do not develop 
Leukemia. This can be perhaps because of a smart 
immune surveillance mechanism in these individuals 
[14]. 
Molecular structure of Bcr and Abl genes: The Bcr 
region contains coiled-coil oligomerization domain 
(amino acid residues from 1 to 69) that forms 
homotetramers, functionally essential domains like 
the serine/threonine kinase domain that undergoes 
self-phosphorylation,guanine exchange factor (GEF) 
domain, guanosine triphosphatase activating protein 
(GAP) domain which regulates p21Rac for cytoskeletal 
reorganization, SH2 domains (two of which interacts 
with  Abl gene). There is a tyrosine residue at 177th 
position (towards N-terminal of BCR portion of 
BCR/ABL protein) that communicates with Grb-2 
(that initiates the Ras signaling pathway) and its 
phosphorylation is essential for leukemogenesis[14]. 
The Abl gene encodes Src-homology (SH) domains, 
a tyrosine kinase domain, DNA-binding domain, 
actin-binding domain, nuclear localization signals 
and proline-rich regions (SH3 motifs), and nuclear 
export signal (at the C-terminus). The four SH3 
motifs interact with the SH3 domains of Crk, Nck, 
GRB2, etc. which mediates the downstream 
pathways [18]. Within the tyrosine kinase domain 
(SH1 domain) there is a tyrosine residue at 393rd 
position that is the primary autophosphorylation site 
[11, 17] (Figure 2). 
Usually, Bcr encodes a serine/threonine kinase which 
interacts with actin, GTP and lipids. Abl encodes for 
a protein tyrosine kinase that transmits signals from 
ligand stimulated growth factor receptors to influence 
cytoskeletal changes mainly. The chimeric Bcr/Abl 
oncogene encodes for an active and constitutive 
tyrosine kinase that phosphorylates target proteins to 
facilitate the expansion of hematopoietic stem cells 
and progenitor cells. The constitutive expression 
occurs because the myristoylated cap region (which 
helps in auto-inhibition of tyrosine kinase) at the N-
terminal of Abl1b gene is replaced by the Bcr 
gene[11, 19, 20](Figure 2).Abl1b and Abl1a are the 
results of alternative splicing of Abl1 (or Abl) gene at 
the first exon. Abl1a is not myristoylated and is also 
expressed at lower levels. It is still not clear what 
takes over the function of myristoyl cap in Abl1a 
[18].  Most of the auto-phosphorylation occurs at the 
tyrosine residues of BCR segment of BCR/ABL 
protein, but the tyrosine kinase activity is attributed 
to the kinase domain of the ABL portion [14]. 
Table 1: Molecular features of the genes Bcr, Abl and the chimeric Bcr/Abl gene 
Feature Bcr gene Abl gene Bcr/Abl gene 
Chromosomal location 22 11 22q11 
Gene size (kb) 130 230 Variable 
Exons 23 11 Variable 
Molecular weight of major proteins 
(kDa) 
130 and 160 145 190, 210 and 230 * 
Cells in which expressed  ubiquitously 
expressed#    
ubiquitously expressed hematopoietic stem 
cells 
Cellular location of the protein  Cytoplasm nucleus and cytoplasm 
@ 
Cytoplasm 
#Highest in the brain and hematopoietic stem cells  
@In neurons and hematopoietic stem cells, mostly cytoplasmic [11]  
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*There are also a few other proteins that have not been given size because they have not been demonstrated on a gel. 
BCR/ABL variants: There are distinct forms of 
Bcr/Abl gene depending on the point of break and 
fusion, each associated with different types of 
leukemia. Three of such clinically significant variants 
identified till date are P190 also referred by some 
researchers as P185 [14] (found in 20-30% of ALL), 
P210 (associated with 95% of CML) [21] and P230 
(present in chronic neutrophilic leukemia) [9, 17]. 
Such variants have a distinct C-terminal due to 
variations in the break-point region,butcommon N-
terminal derived from Abl gene. Sometimes the break 
is 5’ to exons 1a and 1b and sometimes within intron 
1 of Abl gene. But exon 2 (a2) of the Abl gene which 
encodes the SH1 kinase domain is always present in 
the chimeric Bcr/Abl gene [14].The breakpoints in 
major (M) breakpoint cluster region between either 
exons 13 and 14 (b2), or exons 14 and 15 (b3) of Bcr 
gene and its fusion to breakpoints between exon 2 
and 3 (a2) (mostly) of the Abl gene produces the 
b2a2 or b3a2 mRNA that is translated into P210 
BCR/ABL protein. Similarly, P190 BCR/ABL results 
from the e1a2 mRNA formed by fusion between 
breakpoint in minor (m) Bcr gene and a2 and P230 
BCR/ABL is formed from the translation product of 
e19a2 mRNA which involves micro (µ) BCR gene 
[10, 11, 12]. Besides these, there are also some rare 
variants with a breakpoint between exons 6 and 7 
(which forms the P195 protein) and others like the 
P200 and P225 translated from e8a2 and e18a2 
mRNA, respectively. Such variants are the result of 
alternative splicing within the Bcr gene and between 
Bcr and Abl genes besides the difference in 
breakpoint regions of the Bcr gene [14].Although all 
encode tyrosine kinases, there are differences in their 
intrinsic activities and also the downstream signaling 
pathway. For instance, P190 has greater action than 
P210 as well as P230 and Stat6 can be activated by 
P190 and not P210. Unlike P210 and P190, P230 
BCR/ABL cultures are dependent on cytokine for 
growth [17]. It is interesting how minor changes in 
breakpoint location can manifest itself into different 
types of leukemia. This is why the Bcr/Abl fusion 
gene has garnered greater attention from the scientific 
community. Since the presence of Bcr/Abl is highly 
linked to CML, hence focus is given on Bcr/Abl in 
association with CML. The idea is to develop the 
foundation of a precise control technique to “switch 
off” or down-regulate the constitutive tyrosine kinase 
activity by regulating Bcr/Abl at the gene, mRNA or 
protein level. But in this paper, we are emphasizing 
its down-regulation at the mRNA level. 
Chronic Myeloid Leukemia (CML): CML is the 
result of Philadelphia (Ph) chromosome represented 
as t(9;22)(q34;q11) [10] and the molecular weight of 
the fusion protein so formed is 210 kD. This is a type 
of somatic mutation (translocation) and hence not 
heritable. Thus CML is a type of acquired genetic 
disease. However, not all CML has the Ph 
chromosome; although 2016 WHO report states that 
these cases possess the same criteria as Ph-positive 
CML. And hence they are called atypical CML [22, 
23]. It is rare with unknown epidemiological 
indices[23]. The 2016 World Health Organization’s 
revised ‘Blue Book’ of Myeloproliferative 
Neoplasms (MPNs) features Chronic Myeloid 
Leukemia [24]. CML was also included in the 2008 
WHO Blue Book. MPNs are characterized by the 
malignant transformation of pluripotent 
hematopoietic stem cells that maintain their capacity 
of terminal differentiation. This is why the myeloid 
committed precursors form a big pool, and all stages 
of myeloid maturation are identified. In CML the 
white blood cells (WBCs) outnumber the other blood 
cells. Initially, these WBCs function relatively 
normally but as the condition progresses immature 
WBCs or myeloblasts (also called blasts) 
accumulates in the blood and bone marrow.  
However, Chasseriau et al. also mentions that in 
CML there is also increase in megakaryocyte and 
erythroid lineage in peripheral blood and myeloid 
hyperplasia in bone marrow [12, 25 ]. The reason is 
evident since the translocation occurs in HSCs; as a 
result Ph chromosome is also found in neutrophils, 
megakaryocytes, erythroid precursors, B-cells, 
sometimes T-cells and monocytes. Stromal cells of 
the bone marrow are not affected [26]. However, they 
affect malignant hematological cells by positively 
regulating anti-apoptotic proteins [27]. 
Although in 90% to 95% of the cases of CML, the 
presence of Bcr/Abl oncogene is verified [9, 10, 17], 
however many recent studies show an age-related 
correlation to the presence of Bcr/Abl oncogene 
transcript in peripheral blood. This is perhaps 
because with age DNA damage accumulates and the 
presence of secondary mutations further motivates 
leukemia in CML patients [9, 28]. 
Clinical manifestation of CML: A complete blood 
count (CBC) shows elevated platelet count 
(frequently above 106 per µl) with a few functional 
platelets, and cells of various granulopoietic stages, 
basophil, eosinophil and megakaryocyte, WBC count 
is also increased. The peripheral blood smear appears 
to be like a bone marrow aspirate. 
CML is diagnosed based on the percent abundance of 
myeloblast cells. These cells are large and are 
identified because of their lacy chromatin, distinct 
nucleoli, pale cytoplasm, and high nucleus to 
cytoplasm ratio and may exhibit Auer rods (clumps 
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of granular material that arrange as elongated needles 
in the cytoplasm of blast cells).Accordingly, three 
distinct phases have been identified so far in CML 
patients, viz chronic phase (CP), accelerated phase 
(AP) and blast phase (BP). CP may go undetected, 
and therefore in such patients, CML is biphasic with 
only AP and BP at the clinical level [26]. CP is 
clinically manageable but it being asymptomatic is 
somewhat scary because once BP ensues, the 
inevitable result is death [29]. Whenever present, CP 
is clinically characterized by an elevated count of 
myeloid cells in bone marrow, spleen, and peripheral 
blood. The common symptoms include fatigue, 
natural satiety, malaise, weight loss, pain, bleeding 
(due to low and non-functional platelet count), and 
gastrointestinal ulcers (due to elevated histamine 
released from basophilia). Splenomegaly (in 40-50% 
cases) and hepatomegaly (in 10% cases) is also 
observed. WBC count exceeds 100 × 109/L of blood  
[17, 30].Table 2 shows the WHO criteria for AP and 
BP. It is crucial to identify the correct stage of CML 
because of its correlation to the kind of treatment that 
shall best suit the stage and treatment response [21]. 
Table 2: WHO criteria of AP and BP in CML [26] 
Phases WHO criteria 
Accelerated  
Blasts 
Basophils 
Platelets 
 
Spleen and WBC 
 
10-19% 
 ≥20% 
<100 X 109/L (unrelated to therapy) or 1000 x 
109/L (unresponsive to therapy) 
Both spleen size and WBC count increases 
unresponsive to therapy 
Blast 
Blasts 
Extramedullary blasts 
Other 
 
≥20% 
Present 
Large clusters of blasts in bone marrow biopsy 
 
Treatment Implications: Even before the advent of 
Tyrosine Kinase Inhibitors (TKIs), non-specific 
drugs like hydroxyurea (a ribonucleotide reductase 
used to control abnormal blood count), busulfan 
(alkylating agent), and interferon-alfa (IFN-α) were 
used. These did not eliminate the abnormal clones or 
reduce genomic instability to prevent the onset of 
blast phase except for IFN-α which worked to 
provide anti-leukemic immunity. But it had to be 
stopped due to poor tolerance in patients and toxicity 
was also reported when given in combination with 
some other drugs. Allogeneic Stem Cell 
Transplantation (ASCT) with a cure rate of 70% is 
the only curative treatment for CML which also faced 
the limitation of Human Leukocyte Antigen (HLA) 
matched identical sibling. So Auto-transplantation 
(use of graft with Philadelphia negative progenitors 
that can perform normal hematopoiesis) was 
proposed for such patients, but due to the absence of 
graft versus leukemia effect and presence of 
Philadelphia positive cells, it too proved to be a 
failure [10, 58]. The next stage of CML treatment 
saw the rise of TKIs. CML is the first disease to be 
successfully treated with a selective drug designed to 
inhibit the causative tyrosine kinase. Imatinib 
mesylate (Gleevec), called initially STI571 and 
CGP57148B, is the first FDA approved BCR/ABL 
TKI. Since then many more TKIs have been 
approved, and a few are currently under clinical 
trials. Table 3 outlines a comprehensive outlook of 
the most commonly prescribed TKIs mainly focusing 
on their drawbacks such as high cost and associated 
ailments, let alone the resistance that develops due to 
their continuous use. The molecular mechanism of 
such resistance the most common being T315I 
(threonine to isoleucine mutation at the 315th residue 
of BCR/ABL) is due to variations in the target 
domain of ABL kinase of BCR/ABL, increase in 
mRNA and protein level of the oncoprotein [17]. 
Why microRNA? MicroRNAs being highly potent 
open the avenues for its use to even act on targets that 
cannot bereached by the conventional drugs [38].For 
instance, drugs generally work on proteins with 
enzymatic activity or those having an accessible 
conformation, but miRs can be designed to target any 
gene of interest. Moreover, without causing any harm 
to the patient (non-invasiveness), the efficiency of the 
patient to drug response can be evaluated which is a 
boon to save them from the adverse effects of such 
drugs and also to select a personalized drug therapy 
[38, 40]. Based on the miRNA expression profiles 
early treatment is possible and the stage of cancer, 
their sub-types and severity can be monitored. 
 
 
 
 
Asian Pac. J. Health Sci., 2019; 6(1):162-176                                           e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Neog et al                 ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(1):162-176                                     167 
www.apjhs.com       
 
Table 3:Pharmacological properties and a few  adverse effects of TKIs [31]
 
 
Frequency of toxicity   + <1 %       ++ 1-5 %     +++ 
5-10 %     ++++ 10-20 %+++++ 20-30 %       
++++++ >30 % 
Hence, search for an alternative has landed 
researchers on miRNA.  
Micro-RNA: Micro-RNAs (miRs) are approximately 
19-25 nucleotides long, endogenous, evolutionary 
conserved RNAs responsible for post-transcriptional 
regulation of messenger RNAs (mRNAs) [8,21, 32, 
33]. In majority of the cases, miRs target the 3’ 
untranslated region (UTR) of the mRNA (seed match 
sequence) and cause its deadenylation and decapping 
(if there is perfect complementarity between the two) 
and induce translational repression (if 
complementarity is incomplete, mRNA is not 
degraded) [8, 32, 34, 35, 36]. Interactions of miRs 
with 5’ UTR and coding sequences (induce silencing 
of mRNA) and promoter (activate transcription of 
mRNA) has also been observed [35]. They play a 
crucial role in the developmental processes of the 
organism and have been found to influence all cancer 
types investigated to date. The miRs that are 
transported out of the cell via vesicles or with binding 
proteins into the extracellular fluid act as messengers 
of cell-to-cell communication [35].  They are stable 
and thus can be routinely quantitated and potentially 
may also serve as disease biomarkers[33]. The 
human genome contains ~2,500 distinct mature 
miRs[37, 38] and more than one-third of genes are 
putative miR targets[25]. In mammals, miRs which 
are expressed in HSCs are the chief controllers of 
hematopoietic cell lineage differentiation [32, 34]. 
Micro-RNA Biogenesis: miRs are transcribed by 
RNA polymerase II either intragenic (from introns 
and few exons of a protein-coding gene) or intergenic 
(from their promoters independent of another gene) 
regions. Processing is performed by RNA polymerase 
II/III co- or post-transcriptionally. The 5’ end of the 
mature miR has about eight bases at the 5’ end called 
the seed sequence or region [37] and those miRs 
which have similarity in seed sequence are 
transcribed as a long transcript and belong to a family 
[35]. 
In canonical pathway, after transcription of the DNA 
sequence into primary miR, DiGeorge Syndrome 
Critical Region 8 (DGCR8) – an RNA binding 
protein and Drosha (a ribonuclease III) processes it 
into a pre-miR (hairpin RNA). The latter is then 
exported by exportin (XPo) 5/Ran GTP into the 
cytoplasm where Dicer (Type 2 RNase III 
endonuclease whose activity is enhanced by 
Transactivation response element RNA-binding 
protein, TRBP) removes the 3’ loop, and mature 
miRNA duplex is formed. Of the duplex, the strand 
that is loaded into Argonaute (AGO) protein using 
ATP (based on lower 5’ uracil) is called the guide 
strand, and the other is the passenger strand 
(generally degraded or can become functional) [25]. 
The complex of guide strand and AGO so formed is 
called the minimal miR-induced silencing complex 
(mi-RISC). The guide strand now interacts with 
target mRNA based on complementarity, and the 
result can be incomplete or perfect complementarity. 
The consequences of such interactions are explained 
above. The above is the dominant pathway. There 
Year of FDA/EMA approval 2001/2001 2006/2006 2007/2007 2012/2013 2012/2013 
Approximate cost for one month 
supply 
$11053  $12428  $12433  $13078  $13536  
Half-life (hours)  18  3- 5  17  22.5  24  
Mode of elimination  ~81% in 
feces, 
mostly as 
metabolites  
~85% in 
feces, 
mostly as 
metabolites  
~93% in 
feces, 
mostly as 
parent drug  
~91% in feces  ~ 87% in feces  
Neutropenia  ++++++  ++++++  ++++++  ++++  +++++  
Thrombocytopenia  +++++  +++++  ++++++  +++++  ++++++  
Anemia  +++  ++++  ++++  ++++  +++  
Abdominal pain  ++  ++  ++  ++  ++++  
Clinical pancreatitis  +++      
Heart failure  ++  +++  +++    
Pericardial effusion  ++  ++     
Fluid retention/edema  ++  +++  +  +  ++  
Fatigue  ++  ++  ++  ++  ++  
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exists the non-canonical pathway as well. In this 
pathway, Mirtrons are produced from introns of 
mRNA while splicing and without Drosha cleavage 
exported to the cytoplasm by XPo1 (Drosha/DGCR8-
independent pathway). If Drosha is involved, then the 
processed pre-miR is transported via XPo5 to the 
cytoplasm and AGO cleaves one strand. Finally, the 
mi-RISC is formed [21, 35, 39].It is of particular note 
here that the entire process of miR biogenesis and 
miR-mRNA interaction is tightly controlled both 
spatially and temporally in different organisms which 
means microRNA pattern reflects the physiology of a 
cell which can serve as a biomarker in cancer 
including CML. 
MicroRNA and BCR/ABL protein: Use of 
microRNA as a prognostic and diagnostic biomarker 
as well as a therapeutic agent is gaining greater 
importance as the number of researches being carried 
out every year is increasing rapidly. They play a 
pivotal role in cancer both as a tumor suppressor as 
well as a tumor promoter. They can further modulate 
the tumor milieu and immune system because of their 
ability of intercellular communication [40]. The 
gradual inclination towards microRNA is not only 
because the current drug therapies available to treat 
CML are less effective with myriads of side effects 
but also because microRNA has the intrinsic potential 
of RNA interference (RNAi). Moreover, they induce 
either resistance or sensitization to drugs. MicroRNA 
being the icon of RNAi technology can be effectively 
applied to degrade or block the mRNA of tumor 
suppressor proteins and inhibit the cascade of 
downstream signaling pathways of BCR/ABL that 
ultimately result in leukemogenesis. The fact that 
miR therapies are currently under clinical or pre-
clinical trials undeniably shows their great potential 
to treat cancer.The following account focuses on the 
significance of a few miRs as a master regulator of 
Bcr/Abl mRNA. Although the importance of miR as 
a biomarker is not discussed at depth in this account 
separately but examining its expression profile in 
connection with its therapeutic potential surelyserves 
the other purpose as well. 
MicroRNAs directly targeting Bcr/Abl mRNA: 
The presence of specific sequences in Bcr/Abl 
mRNA provides an efficient means to control it by 
miR[10]. Differential expression of many miR in 
CML as compared to normal cells show that these 
miRs regulate the progression of leukemia. Table 4 
shows the identified miR that directly targets the 
mRNA of the oncogene or Abl. 
Table 4: Features of miRthat targetsBcr/Abl and/or Abl mRNA. 
MicroRNA Location Target Role Expression level Reference  
miR-29b 7q32.3 Abl Anti-proliferative and pro-apoptotic 
effect on cells 
↓ [41]  
miR-320a 8p21.3 Bcr/Abl Inhibits invasion, Anti-proliferative 
and pro-apoptotic effect on cells 
↓ [41]  
miR-30a 
miR-30e 
6q13 
1p34.2 
Abl 
Bcr/Abl 
Regulator of cell cycle progression ↓ [41]  
miR-424 
(oncogene) 
Xq26.3 Bcr/Abl Inhibits apoptosis and promotes cell 
proliferation 
↑ [41]  
miR-7 9 Abl Induces Apoptosis ↓ [42]  
miR-23a 19 Bcr/Abl Targets BCR/Abl/PI3K/AKT/MMP9 
signaling pathway 
↓ [42]  
miR-143 5 Bcr/Abl Induces apoptosis in K562 cell line ↓ [42]  
 
BCR/ABL has been the target of the TKIs as well 
because this oncoprotein activates many of the 
downstream pathways that inhibit apoptosis and cell 
differentiation, induces cell proliferation and 
migration [29].The theoretical promise of miR as a 
therapeutic agent to target Bcr/Abl mRNA does have 
specific technical issues. For instance, the half-life of 
P210 BCR/ABL protein is more than 24 hours which 
means that prolonged ex-vivo culture is needed to 
induce death in most leukemic cells. Besides, studies 
show that Bcr/Abl mRNA and protein is not 
expressed in all CML stem cells and so residual 
leukemic cells would soon take over the former[10]. 
Circulating microRNA levels are extracted from 
venous plasma, or serum or exosomalmiRs in 
peripheral blood and often several miRs are reported 
to express differently in plasma, serum or exosomes. 
Thus, choice of a proper selection method for certain 
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miRs should not be denied [43].It is crucial that 
downstream targets be also targeted by microRNA, 
and a combinatorial approach is made into treating 
CML. 
MicroRNAs regulating downstream targets of 
BCR/ABL:  
The most directly linked domains to Abl kinase 
constitutive activation are the coiled-coil (CC) 
domain (at the N-terminal) and a tyrosine residue at 
177th position (Y177) of the BCR portion of the 
chimeric gene [13, 20,44]. As already mentioned the 
CC domain helps in dimerization (two monomers 
dimerize) or tetramerization (dimers stacking) of the 
oncoprotein which increases the kinase activity 
making the cell resistant to imatinib[13, 17, 20]. It 
also causes autophosphorylation of Y177 allowing 
occurrence of myelogenous disease similar to 
leukemia by BCR/ABL downstream  interactions that 
is responsible for the expansion, proliferation, and 
survival of leukemic cells. The Y177 is the site where 
downstream signaling molecules like GRB2, GRB10, 
14-3-3 interact [18]. The investigation of such 
signaling pathways thus becomes the pre-requisite 
before the miRs that regulate them are identified. It is 
noteworthy that a significant number of such 
interactions between BCR/ABL and other proteins 
remain to be revealed. Bcr/Abl encodes for a 
cytoplasmic tyrosine kinase that is oncogenic only 
when expressed in HSCs with self-renewal potential. 
The HSC transforms into leukemic stem cell (LSC) 
that generate an enormous number of leukemic 
progenitor cells during the chronic phase which loses 
their capacity to self-renew and finally differentiate 
into mature cells. The expansion, proliferation, 
genetic as well as epigenetic aberrations, arrested 
differentiation and drug resistance are what guide the 
transition from chronic to blast phase [57].Cardama 
and Cortes [18] provided a model to explain the 
interplay of several components in the transformation 
of HSC to LSC and transition through phases of 
CML. In the model, events described are Bcr/Abl 
expression (e.g. by expression of ICSBP or loss of 
JUNB), activation of anti-apoptotic and anti-
senescence genes (e.g. TERT), evasion of immune 
system, arrested differentiation (e.g. by silencing of 
C/EBPα), loss of tumor suppressors and activation of 
self-renewal pathway (e.g. β-catenin) [18]. 
BCR/ABL kinase perhaps reduces the fidelity of 
DNA repair mechanisms and allows point mutations 
and deletions to take place in LSCs. A few of the 
pathways involved in leukemogenesis and 
transforming activity are discussed here. 
Pathway involved in disruption of cellular 
differentiation: Y177 of Bcr/Abl is the primary 
docking site for the SH2 domain of GRB2 (Growth 
factor receptor-bound protein 2). The interaction 
recruits SOS (son of sevenless) which is a guanine 
nucleotide exchanger of RAS. RAS activation is 
shown to be mediated by Shc proteins [14, 36]. Shc 
protein interacts with the SH2 domain of GRB2 and 
Shc/GRB2/SOS is as well involved in RAS activation 
[36]. RAS and GAB2 (GRB2-associated binding 
protein 2) are activated via phosphorylation of the 
tyrosine kinase. GRB2/GAB2 complex results in 
constitutive activation of PI3K/AKT 
(phosphatidylinositol 3-kinase/Protein kinase B) (not 
shown in the figure) and ERK (extracellular signal-
regulated kinase) in primary myeloid cells [10, 18, 
20]. Besides, CRKL (Crk-like protein), an adaptor 
protein of SH2/SH3, also activates RAS as well as 
JUN and is oncogenic that is important in fibroblast 
transformation by BCR/ABL. Farnesyl-transferase 
inhibitors have been shown to block mutant as well 
wild-type RAS signaling pathway. GAB-/- mice fail 
to undergo differentiation [18]. The 
RAS/RAP1/MEK/ERK is the central pathway 
involved in signal transmission from cell-surface 
receptors to transcription factors in the nucleus. 
GRB2/GAB2 activates B-RAF kinase that is an 
effector molecule of RAP1 (RAS-related protein). 
This, in turn, activates MEK/ERK pathway that 
stabilizes hnRNP-E2 (heterogeneous nuclear ribo 
nucleoprotein E2). hnRNP-E2 is not detected in CP 
but only in BP which suppresses the mRNA levels of 
C/EBPα (CCAAT/enhancer binding protein) as a 
result of which myeloid precursors fail to 
differentiate into granulocyte-monocyte progenitor 
cells[20, 45]. This occurs during the CP to BP 
transition. Consistent with these facts Yin et al. 
(2017) found that C/EBPα is expressed in CP but lost 
in BP of CML [18, 46].  In P210 BCR/ABL 
expressing cells, the effects of C/EBPα is partly 
dependent on the repression of GATA-2 (GATA-
binding factor 2, a transcription factor that is critical 
for self-renewal, maintenance and differentiation of 
HSCs[47]. The above effects related toC/EBPα 
deregulation is shown to be reversed by imatinib. 
Scherr et al.(2006) used RNAi to reduce GAB2 
protein expression in CML CD34+ cells and found 
that that inhibited Bcr/Abl dependent proliferation 
[48].   
Pathways for cell survival and proliferation: 
Interaction of Bcr/Abl with cytokine receptors 
activates JAK1-3 (Janus Kinase) which further 
activates STAT1, 3, 5 and 6 (Signal transducers and 
activators of transcription). JAK2/STAT5 pathway 
directly leads to cell survival by transcriptionally 
activating BCL-XL (B-cell lymphoma--extra-large, 
anti-apoptotic protein). Besides, BCR/ABL directly 
abrogates the transcription of ICSBP (Interferon 
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Consensus Sequence Binding Protein) and releases 
its inhibitory effect on anti-apoptotic genes helping in 
cell survival [18]. Activation of JAK2 directly 
phosphorylates Y177 and hence stabilizes and 
enhances BCR/ABL signaling pathways which is 
indispensable for leukemogenesis.Moreover, JAK2 
activates c-MYC oncogene and protects the 
oncoprotein from degradation. In contrast, C/EBPα 
causes transcriptional repression of c-MYC. But 
since, C/EBPα is lost during BP, so c-MYC is 
overexpressed, and this activates Survivin via 
JAK2/PI3K pathway which leads to cell proliferation 
and survival [20]. JAK2 knockdown or inhibition 
inhibits STAT5 and RAS/PI3K. 
PI3K/AKT pathway also activates MDM2, the chief 
negative regulator of TP53 (Tumor suppressor 
protein 53). TP53 is critical in determining the cell's 
fate and sensitivity to treatment. TP53 
inactivation/disruption which frequently occurs in 
CML and most of the cancers causes unavailability of 
P21 (it acts as a stop signal for cell division) that 
results in the escape of cell cycle checkpoints and 
uninterrupted proliferation. This pathway also 
induces activation of SKP2 (S-phase kinase-
associated protein 2), a ubiquitin E3 ligase which is 
turn activates AKT (positive feedback loop) and also 
targets cell cycle control elements like P21 resulting 
in progression of CML. SKP2 is an established proto-
oncogene. SKP2 inhibitors are novel therapeutic 
cancer strategy currently under investigation [59]. 
IKK-β (inhibitor of nuclear factor kappa-B kinase 
subunit beta) activated via the PI3K/AKT pathway 
phosphorylates IκBα which is an inhibitor of NF-κB 
(Nuclear Factor kappa-light-chain-enhancer of 
activated B cells). Once IκBα has phosphorylated it 
dissociates from its target, NF-κB.  NF-κB then 
migrates to the nucleus and protects the cell from 
apoptosis, induces cell proliferation and cell death 
evasion [49]. NF-κB is considered to be a partner of 
BCR/ABL and is constitutively activated in most of 
the cancers thereby providing an attractive target of 
cancer therapy including CML.The FoxO3a 
(Forkhead box O3) is a transcription factor that 
triggers apoptosis by upregulating apoptotic genes. It 
regulates the Notch signaling pathway (a highly 
conserved pathway that regulates quiescence in adult 
stem cells) and suppresses cell cycle. AKT can 
directly phosphorylate it and thus mediate its 
interaction with 14-3-3 nuclear export protein so that 
it is not able to re-enter the nucleus. Phosphorylated 
FoxO3a is also the target of ubiquitin ligase E3 ligase 
and is finally degraded [50]. IKK-β can also 
phosphorylate it. C/EBPα is a positive regulator of 
FoxO3a, but it is lost in BP. This in turn causes 
FoxO3a reduction and ultimately the reduction of 
TRAIL (Tumor Necrosis Factor Related Apoptosis-
Inducing Ligand). Hence, apoptosis is inhibited. 
Figure 3 portrays the most studied signaling 
pathways involved in leukemogenesis in CML. 
 
Figure 3: Downstream signaling pathways of BCR/ABL in CML.Peach coloured shapes indicate kinase; 
yellow coloured shapes indicate established oncoproteins; blue coloured shapes indicate established tumor 
suppressor proteins, and other colours indicate proteins present in normal cells. Arrow indicates activation 
whereas line with a bar indicates inhibition.   (adapted from Kang et al. [20] and redrawn). 
The following tables 5 to 10 show the various microRNAs that naturally target signaling molecules mentioned in the 
above pathways [21,36, 41, 42]. Target detection methods that are mostly used are qPCR, western blot analysis, 
luciferase activity assay, microarray expression profiles. MicroRNA based bioinformatics tools like TargetScan, 
miRbase, and miRNAMap are readily available and user-friendly target prediction tools that generally search for the 
seed region match. To establish the potentiality of microRNA, multiple functional analysis supported by 
experiments in cell lines as well as patient samples is required. The following account mentions the most studied 
microRNAs involved in CML after thorough experimentation. 
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Table 5: MicroRNA targeting RAS in CML 
MicroRNA Chromosomal Location 
miR-124-3p 8 
miR-1271-5p 5 
miR-145-5p 5 
miR-148a-3p 7 
miR-152-3p 17 
miR-183-5p 7 
miR-19a-3p 13 
miR-196a-5p 17 
miR-200b-3p 1 
miR-200c-3p 12 
miR-218-5p 4 
miR-22-3p 17 
miR-29a-3p 7 
miR-429 1 
miR-506-3p X 
miR-96-5p 7 
miR-98-5p X 
 
Table 6: MicroRNA targeting GAB2 in CML 
MicroRNA Chromosomal Location 
miR-125a-5p 19 
miR-218-5p 4 
 
Table 7: MicroRNA targeting GRB2 in CML 
MicroRNA Chromosomal Location 
miR-124-3p 8 
miR-1271-5p 5 
miR-128-3p 2 
miR-141-3p 12 
miR-153-3p 2 
miR-182-5p 7 
miR-200a-3p 1 
miR-216a-3p 2 
miR-27a-3p 19 
miR-27b-3p 9 
miR-3681-3p 2 
miR-96-5p 7 
 
Table 8: MicroRNA targeting STAT5 in CML 
MicroRNA Chromosomal Location 
miR-141-3p 
 
12 
miR-194-5p 
 
1 
miR-200a-3p 1 
miR-23a-3p 
 
19 
miR-23b-3p 
 
9 
miR-23c X 
miR-130a-5p 11 
mir-150-5p 19 
mir-2278 9 
 
Table 9: MicroRNA targeting PI3K in CML 
MicroRNA Chromosomal Location 
miR-124-3p 8 
miR-130a-3p 11 
miR-135a-5p 3 
miR-130-3p 11 
miR-135a-5p 3 
miR-137 1 
miR-15a-5p 13 
miR-153-3p 2 
miR-16-5p 13 
miR-181a-5p 9 
miR-19a-3p 13 
miR-195-5p 17 
miR-199-3p 19 
miR-200b-3p 1 
miR-200c-3p 12 
miR-218-5p 4 
miR-25-3p 7 
miR-27a-3p 19 
miR-29a-3p 7 
miR-30-5p 6 
miR-301-3p 17 
miR-32-5p 9 
miR-363-3p X 
miR-365a-3p 16 
miR-367-3p 4 
miR-424-5p X 
miR-429 1 
miR-454-3p 17 
miR-497-5p 17 
miR-506-3p X 
miR-7-5p 9 
miR-9-5p 1 
miR-92a-3p 13 
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Table 10: MicroRNA targeting CRLK in CML 
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Table 11:Some of the other microRNAs involved in recently discovered signaling pathways are mentioned in 
the following table [42] 
MicroRNA (tumour suppressor) Target Role 
Mir-155  CEBPβ  Increases apoptosis  
Mir-7  Abl, PI3K, AKT  Increases apoptosis and sensitizes K562 cells 
to imatinib  
MIR-186  ROCK1  Inhibits cell proliferation and migration  
Mir-570  IRS1, IRS2  Increases apoptosis, suppresses cell 
proliferation, decreases glucose metabolism  
Mir-15a-5p  CXCL10  Suppresses cell proliferation, promotes 
apoptosis  
Mir-150  FOXOB, EIF4B, 
PRKCA, TET3  
Proteoglycan metabolism in cancer, mTOR or 
Wnt signaling pathway  
Mir-139-5p  Brg1  Suppresses differentiation and proliferation  
Mir-219  XIAP  Inhibits survival of leukemic cells  
Mir-203  Survivin, Bmi-1  In LSCs, the miRNA increases cell 
proliferation and self-renewal capacity  
Mir-130a  BCL-2, MCL-1, XIAP  Promotes apoptosis  
Mir-708  IKKβ  Suppresses NFκB pathway  
Mir-186  DDX43  Inhibits cell proliferation and increases 
apoptosis  
Mir-202  HK2  Inhibits glycolysis  
Mir-181a  RALA  Inhibits growth and apoptosis, sensitizes cells 
to imatinib  
Mir-148b  DNMT1 and DNMT3  Inhibits cell proliferation and invasion  
Mir-2278  AKT2, STAM2  Inhibits proliferation of resistant leukemic 
cells and promotes apoptosis  
Mir-486-5p  PTEN, FOXO1  Role in modulation of normal as well as 
hematopoietic progenitor growth  
MicroRNA (Oncogene)    
Mir-17-92  A20 (TNFAIP3)  Regulates NFκB pathway  
Mir-301a  TIMP2  Promotes cell proliferation and inhibits 
apoptosis  
Mir-362-5p  GADD45α  Inhibits apoptosis and promotes cell 
proliferation  
Mir-99a  CTDSPL and TRIB2  Inhibits apoptosis and promotes cell 
proliferation  
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Target detection methods that are mostly used are 
qPCR, western blot analysis, luciferase activity assay, 
microarray expression profiles. MicroRNA based 
bioinformatics tools like TargetScan, miRbase, and 
miRNAMap are readily available and user-friendly 
target prediction tools that generally search for the seed 
region match. To establish the potentiality of 
microRNA, multiple functional analysis supported by 
experiments in cell lines as well as patient samples is 
required. The following account mentions the most 
studied microRNAs involved in CML after thorough 
experimentation. 
Mir-150 is found to downregulate in both CP and BP 
significantly and were not restored in patients resistant 
to imatinib which implies that it can be used as a 
biomarker in treatment response [51]. 
Several studies confirm that Mir-203 expression is 
significantly down-regulated in CML cell lines but not 
in other MPNs. Reintroduction of the miR resulted in a 
marked decrease of the oncoprotein [52]. Thus, mir-
203 can be a diagnostic biomarker in CML. 
Mir-17/92 cluster includes mir-17, mir-19a, mir-19b 
and mir-20a. The members of this cluster are shown to 
overexpress in CML. Specially overexpression of mir-
20a only in K562 CML cell line and not in AML cell 
line shows its potential to be a biomarker of CML 
[53].Mir-10a targets upstream stimulatory factor 1 
(USF1) which is an established transcription factor of 
cell proliferation upregulated to different extents in 
CML patients. However, its use as a biomarker of drug 
response requires further investigation as the results 
from various CML cell lines do not show consistency 
[54].Its overexpression in K562 cells is shown to arrest 
the G1 phase by activation of p21 and p27 [55].Mir-
221 expression is found to decrease in patients with 
imatinib resistance. Its restoration and knockdown of 
STAT5 in K562 cells reduced BCL2:Bax ratio and 
increased the sensitivity of the cells to imatinib 
treatment [56]. 
 
Conclusion 
 
 In-depth analysis about microRNA expression profile 
concerning any cancer including leukemia allows it to 
be used as an antagomir (or anti-miR) or as a miRNA 
mimic. Anti-miR suppresses the function of 
endogenous miRNAs thus providing an avenue to 
inhibit the role of oncogenic miRNAs that are often 
over-expressed in cancer. This approach is called 
miRNA inhibition. In contrast, a mimic is used in 
replacement approach to function as an endogenous 
miRNA thereby enhancing the effect of tumor 
suppressor microRNA [60]. Both methods require the 
introduction of synthetic miRNA [38]. In this regard 
use of small interfering RNAs (siRNAs) as a 
therapeutic agent is often discussed. But unlike 
miRNA, they cannot be used for prognosis and 
diagnosis and to evaluate treatment response. Besides, 
both share common hurdle of relative stability. In vivo 
introduction of miRNA can also trigger the innate 
immunity via Toll-like receptors. However, studies 
show that these problems are manageable by their 
smart chemical modification [38, 43]. 
However, as compared to siRNA the clinical 
development of miRNA is lagging probably due to 
uncertainty in their action and specificity. Till date only 
two of them namely, MRX34 (miRNA-34a mimic) for 
primary liver cancer and TargomiRs (miRNA-16 
mimic) for malignant pleural mesothelioma has 
reached phase 1 clinical trials. A few of the miRNAs 
involved in CML are also under pre-clinical phases. It 
is important to note that miRNAs are advantageous 
when it comes to the treatment of complex diseases 
like cancer or neurodegenerative diseases because it 
involves targeting several genes at once and also 
miRNA can target, any target gene inaccessible to 
drugs. Besides, a combinatorial approach to treating 
CML with TKIs after sensitizing cells to TKIs by use 
of microRNAs to avoid drug resistance is another 
promising therapeutic aspect. With the rapid 
advancement in microRNA research and understanding 
of signaling network in CML, and simultaneously 
managing problems of miRNA delivery systems, it can 
be expected that miRNA therapeutics in the clinic will 
soon be a reality. 
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